What diseases and conditions are specifically included in the indications of Enzalutamide/Enzalutamide (Anchortan)?

Enzalutamide/Enzalutamide ( Enzalutamide) is an androgen receptor inhibitor mainly used to treat prostate cancer. It blocks the effects of androgens by inhibiting the binding of androgens to receptors, thereby reducing the growth and spread of prostate cancer cells. Enzalutamide has a wide range of indications, covering patients with prostate cancer at different stages. Specific indications include:

1. Castration-resistant prostate cancer (CRPC)

Enzalutamide is most commonly used to treat patients with castration-resistant prostate cancer. Castration-resistant prostate cancer occurs when the tumor continues to grow in a male hormone-low environment after androgen levels are suppressed through surgery or drugs (castration therapy). Enzalutamide can further prevent androgen from stimulating prostate cancer cells by inhibiting androgen receptors, thereby effectively slowing down the progression of cancer and improving patient survival.

2. Metastatic castration-sensitive prostate cancer (mCSPC)

Enzalutamide has also shown promising efficacy in metastatic castration-sensitive prostate cancer. The prostate cancer in such patients usually responds to castration therapy, but over time, it may transform into castration-resistant prostate cancer. Enzalutamide, as an androgen receptor inhibitor, can enhance the inhibitory effect on castration-sensitive cancer cells and slow down the progression of tumors, especially when combined with chemotherapy or other drugs.

3. Biochemical recurrence of non-metastatic castration-sensitive prostate cancer with high risk of metastasis

Biochemical recurrence means that after treatment for prostate cancer, although imaging examinations do not show metastatic lesions, the level of prostate-specific antigen (PSA) in the patient's blood increases, indicating that the cancer may recur. Enzalutamide is particularly important in these patients with non-metastatic castration-sensitive prostate cancer who are at high risk for metastasis. By inhibiting the androgen receptor, enzalutamide helps delay disease progression and reduce the risk of metastasis in patients, especially when PSA levels continue to rise but no obvious metastasis has occurred.

Reference materials:https://www.xtandi.com/